Active Ingredient History
Tucatinib, sold under the brand name Tukysa, is a small molecule inhibitor of HER2 for the treatment of HER2-positive breast cancer. It was developed by Array BioPharma and licensed to Cascadian Therapeutics. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Adenocarcinoma (Phase 1)
Biliary Tract Neoplasms (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Central Nervous System Diseases (Phase 1/Phase 2)
Cholangiocarcinoma (Phase 1)
Colorectal Neoplasms (Phase 2)
Drug Interactions (Phase 1)
Esophageal Neoplasms (Phase 3)
Gallbladder Neoplasms (Phase 1)
Healthy Volunteers (Phase 1)
Liver Diseases (Phase 1)
Meninges (Phase 2)
Neoplasms (Phase 2)
Stomach Neoplasms (Phase 3)
Urologic Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue